RNA-based Therapeutics Market Size, Share & Trends Analysis Report By Product (Vaccines, Drugs), By Type (mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, RNA Aptamer, Other Therapeutics), By Indication (Infectious Diseases, Rare Genetic Diseases/Hereditary Diseases, Oncology, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Others), By Delivery Mechanism (Lipid Nanoparticles (LNPs), Polymer-Based Nanoparticles, Viral Vectors, Naked RNA), By End User, By Region and By Segment Forecasts, 2025-2034

Report Id: 1151 Pages: 185 Last Updated: 08 November 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

RNA-based Therapeutics Market Segmentation:

RNA-based Therapeutics Market by Product-

  • Vaccines
  • Drugs

RNA-based Therapeutics Market

RNA-based Therapeutics Market Based on Type-

  • mRNA Therapeutics
  • RNA Interference (RNAi) Therapeutics
  • Antisense Oligonucleotide (ASO) Therapeutics
  • RNA Aptamer
  • Other Therapeutics

RNA-based Therapeutics Market Based on Indication-

  • Infectious Diseases
  • Rare Genetic Diseases/Hereditary Diseases
  • Oncology
  • Ophthalmology
  • Hematological Disorders
  • Acute Hepatic Porphyria (AHP)
  • Others

RNA-based Therapeutics Market Based on End-User-

  • Hospitals and Clinics
  • Research Settings

RNA-based Therapeutics Market By Delivery Mechanism-

  • Lipid Nanoparticles (LNPs)
  • Polymer-Based Nanoparticles
  • Viral Vectors
  • Naked RNA

RNA-based Therapeutics Market Based on Region-

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Chapter 1.    Methodology and Scope
1.1.    Research Methodology
1.2.    Research Scope & Assumptions

Chapter 2.    Executive Summary

Chapter 3.    Global RNA-based Therapeutics Market Snapshot

Chapter 4.    Global RNA-based Therapeutics Market Variables, Trends & Scope
4.1.    Market Segmentation & Scope
4.2.    Drivers
4.3.    Challenges
4.4.    Trends 
4.5.    Investment and Funding Analysis 
4.6.    Porter's Five Forces Analysis
4.7.    Incremental Opportunity Analysis (US$ MN), 2025-2034 
4.8.    Global RNA-based Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9.    Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10.    Use/impact of AI on RNA-BASED THERAPEUTICS MARKET Industry Trends 

Chapter 5.    RNA-based Therapeutics Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1.    Market Share by Product, 2024 & 2034
5.2.    Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:

5.2.1.    Vaccines
5.2.2.    Drugs 

Chapter 6.    RNA-based Therapeutics Market Segmentation 2: By Indication, Estimates & Trend Analysis
6.1.    Market Share by Indication, 2024 & 2034
6.2.    Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:

6.2.1.    Infectious Diseases
6.2.2.    Rare Genetic Diseases/Hereditary Diseases
6.2.3.    Oncology
6.2.4.    Ophthalmology
6.2.5.    Hematological Disorders
6.2.6.    Acute Hepatic Porphyria (AHP)
6.2.7.    Others 

Chapter 7.    RNA-based Therapeutics Market Segmentation 3: By Type, Estimates & Trend Analysis
7.1.    Market Share by Type, 2024 & 2034
7.2.    Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:

7.2.1.    mRNA Therapeutics
7.2.2.    RNA Interference (RNAi) Therapeutics
7.2.3.    Antisense Oligonucleotide (ASO) Therapeutics
7.2.4.    RNA Aptamer
7.2.5.    Other Therapeutics 

Chapter 8.    RNA-based Therapeutics Market Segmentation 4: By Delivery Mechanism, Estimates & Trend Analysis
8.1.    Market Share by Delivery Mechanism, 2024 & 2034
8.2.    Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery Mechanism:

8.2.1.    Lipid Nanoparticles (LNPs)
8.2.2.    Polymer-Based Nanoparticles
8.2.3.    Viral Vectors
8.2.4.    Naked RNA 

Chapter 9.    RNA-based Therapeutics Market Segmentation 5: By End-User, Estimates & Trend Analysis
9.1.    Market Share by End-User, 2024 & 2034
9.2.    Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User:

9.2.1.    Hospitals and Clinics
9.2.2.    Research Settings 

Chapter 10.    RNA-based Therapeutics Market Segmentation 6: Regional Estimates & Trend Analysis
10.1.    Global RNA-based Therapeutics Market, Regional Snapshot 2024 & 2034
10.2.    North America

10.2.1.    North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

10.2.1.1.    US
10.2.1.2.    Canada

10.2.2.    North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.2.3.    North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.2.4.    North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.2.5.    North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Delivery Mechanism, 2021-2034
10.2.6.    North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034

10.3.    Europe

10.3.1.    Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

10.3.1.1.    Germany
10.3.1.2.    U.K.
10.3.1.3.    France
10.3.1.4.    Italy
10.3.1.5.    Spain
10.3.1.6.    Rest of Europe

10.3.2.    Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.3.3.    Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.3.4.    Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.3.5.    Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Delivery Mechanism, 2021-2034
10.3.6.    Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034

10.4.    Asia Pacific

10.4.1.    Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

10.4.1.1.    India 
10.4.1.2.    China
10.4.1.3.    Japan
10.4.1.4.    Australia
10.4.1.5.    South Korea
10.4.1.6.    Hong Kong
10.4.1.7.    Southeast Asia
10.4.1.8.    Rest of Asia Pacific

10.4.2.    Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.4.3.    Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.4.4.    Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
10.4.5.    Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Delivery Mechanism, 2021-2034
10.4.6.    Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034

10.5.    Latin America

10.5.1.    Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

10.5.1.1.    Brazil
10.5.1.2.    Mexico
10.5.1.3.    Rest of Latin America

10.5.2.    Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.5.3.    Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.5.4.    Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.5.5.    Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Delivery Mechanism, 2021-2034
10.5.6.    Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034

10.6.    Middle East & Africa

10.6.1.    Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

10.6.1.1.    GCC Countries
10.6.1.2.    Israel
10.6.1.3.    South Africa
10.6.1.4.    Rest of Middle East and Africa

10.6.2.    Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.6.3.    Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.6.4.    Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.6.5.    Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Delivery Mechanism, 2021-2034
10.6.6.    Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034

Chapter 11.    Competitive Landscape
11.1.    Major Mergers and Acquisitions/Strategic Alliances
11.2.    Company Profiles

 
11.2.1.    Biogen Inc.

11.2.1.1.    Business Overview
11.2.1.2.    Key Product/Service Type
11.2.1.3.    Financial PerProductance
11.2.1.4.    Geographical Presence
11.2.1.5.    Recent Developments with Business Strategy

11.2.2.    TME Pharma
11.2.3.    IVERIC bio (Astellas Pharma)
11.2.4.    Olix Pharmaceuticals
11.2.5.    GlaxoSmithKline Plc
11.2.6.    Sanofi S.A
11.2.7.    Alnylam Pharmaceuticals
11.2.8.    Ionis Pharmaceuticals
11.2.9.    Benitec Biopharma Ltd
11.2.10.    Acuitas Therapeutics
11.2.11.    Arbutus Biopharma
11.2.12.    Silence Therapeutics Plc
11.2.13.    Enzon Pharmaceuticals Inc
11.2.14.    Bio-Path Holdings Inc.
11.2.15.    Calando Pharmaceuticals (Arrowhead Pharmaceuticals Inc.)
11.2.16.    Percheron Therapeutics Limited
11.2.17.    Gene Signal
11.2.18.    Gradalis
11.2.19.    iCo Therapeutics
11.2.20.    Aptose Biosciences
11.2.21.    Viridian Therapeutics, Inc.
11.2.22.    Mirna Therapeutics Inc (Synlogic, Inc.)
11.2.23.    Adhera Therapeutics
11.2.24.    Achieve Life Sciences, Inc. 
11.2.25.    Syntara Limited
11.2.26.    Rexahn Pharmaceuticals (Ocuphire Pharma, Inc.)
11.2.27.    Regulus Therapeutics (Novartis)
11.2.28.    Phio Pharmaceuticals Corp.
11.2.29.    Santaris Pharma A/S (Roche)
11.2.30.    Sarepta Therapeutics
11.2.31.    Sirnaomics Inc.
11.2.32.    Dicerna Pharmaceuticals (Novo Nordisk)
11.2.33.    Others 

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
3553
Security Code field cannot be blank!

Frequently Asked Questions

RNA-based Therapeutics Market is valued at USD 12.4 Billion in 2024 and is predicted to reach USD 22.6 Billion by the year 2034

Global RNA-based Therapeutics Market is expected to grow at a 6.5% CAGR during the forecast period for 2025-2034.

RNA-based Therapeutics Market Companies are Biogen Inc., TME Pharma, IVERIC bio (Astellas Pharma), Olix Pharmaceuticals, GlaxoSmithKline Plc, Sanofi S.A, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Benitec Biopharma Ltd, Acuitas Therapeutics, Percheron Therapeutics Limited, Gene Signal, Gradalis, iCo Therapeutics, Aptose Biosciences, Viridian Therapeutics, Inc., Mirna Therapeutics Inc (Synlogic, Inc.), Adhera Therapeutics, Achieve Life Sciences, Inc., Syntara Limited, Rexahn Pharmaceuticals (Ocuphire Pharma, Inc.), Regulus Therapeutics (Novartis), Phio Pharmaceuticals Corp., Santaris Pharma A/S (Roche), Sarepta Therapeutics, Sirnaomics Inc., Dicerna Pharmaceuticals (Novo Nordisk) and Others

Product, Type, Indication, End-User and Delivery Mechanism are the key segments of the RNA-based Therapeutics Market.

North America region is leading the RNA-based Therapeutics Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying